News FAMHP

There are 919 result(s) found based on your search criteria

1-10 from 919 result(s)

In-house medical software: registration and legislation for health institutions

Healthcare institutions often develop their own software to support patient care. This software has to comply with the legal requirements and obligations described below.

The FPS Public Health and the FAMHP invite you to participate in the public consultation on a clinical trial of the genetically modified medicine SPVN20 for the treatment of rod-cone dystrophy. The public consultation will take place from 19 May to 18 Jun

The FPS Public Health and the FAMHP invite you to participate in the public consultation on a clinical trial of the genetically modified medicine SPVN20 for the treatment of rod-cone dystrophy. The public consultation will take place from 19 May to 18 June 2025.

PRAC May 2025 - New risk mitigation measures for finasteride and dutasteride and start of a review of the Ixchiq vaccine

At its May 2025 meeting, the European Medicines Agency Risk Assessment Committee proposed new risk mitigation measures for finasteride and dutasteride. Suicidal thoughts were confirmed as an adverse effect for finasteride, but not for dutasteride. Belgium does not agree with the conclusion. The PRAC also initiated a review of Ixchiq (live attenuated chikungunya vaccine) following reports of serious adverse events in elderly people.

Give your opinion on a genetically modified medicine for haemophilia B

The FPS Public Health and the FAMHP invite you to participate in the public consultation on a clinical trial of the genetically modified medicine CSL222 for the treatment of haemophilia B. The public consultation will take place from 28 April to 28 May 2025.

REMINDER - Marketing stop of Depakine (sodium valproate) 300 mg/5 ml syrup: beware of medication errors

As announced in December 2024, Sanofi Belgium has decided to stop marketing Depakine 300 mg/5 ml syrup as of 28 April 2025. Depakine's other oral liquid formulation, the 300 mg/ml oral solution, will remain available in Belgium. As the latter is more concentrated than the syrup and dosed with a different device, patients, healthcare professionals and parents need to be informed and prepared to avoid potential medication errors.

Recall of batches of Genta-Equine 100 mg/ml solution for injection

Following an increased number of reports of anaphylactic reactions in horses after the administration of Genta-Equine 100 mg/ml, two batches are being recalled in Belgium. These are batches T-001 (expiry date 30 April 2025) and V-001 (expiry date 30 April 2026).

Conformity check of veterinary prescriptions models temporarily not a priority

As not all veterinarians yet have prescriptions in line with the new legislation, the FAMHP has issued a circular asking its inspection services to no longer give priority to checking the conformity of these model prescriptions.

FAMHP joins Instagram!

To better inform and raise awareness among Belgian citizens, the FAMHP launches its Instagram account where content suited to this platform will be shared: infographics, practical tips, news on medicines and healthcare products, and much more.

Flash VIG-news :Progestin-associated meningioma risk: current situation and recommendations

Certain progestins have been associated with an increased risk of meningioma. The FAMHP reminds healthcare professionals of measures to minimise the risk of meningioma associated with these progestins.

The new biovigilance forms are now available

Are you a Belgian tissue establishment or hospital? From now on, you should report all serious adverse events (SAEs) and serious adverse reactions (SARs) to the FAMHP Biovigilance Entity using the new forms.

1-10 from 919 result(s)